1fd89d3a-5991-4bfb-b27f-66b5f2a289d8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- HEDGEHOG_SIGNALING+0.400
- NOTCH_SIGNALING+0.400
- TGF_BETA_SIGNALING+0.400
- E2F_TARGETS+0.300
- G2M_CHECKPOINT+0.300
- KRAS_SIGNALING_UP+0.300
- MITOTIC_SPINDLE+0.300
- WNT_BETA_CATENIN_SIGNALING+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- OXIDATIVE_PHOSPHORYLATION-0.500
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- BILE_ACID_METABOLISM-0.300
- FATTY_ACID_METABOLISM-0.300
- PROTEIN_SECRETION-0.300
- ADIPOGENESIS-0.200
- ANDROGEN_RESPONSE-0.200
- HEME_METABOLISM-0.200
- INTERFERON_ALPHA_RESPONSE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 824433bf-151c-46ea-9ea7-f53813f66a97 | — | — | 0.818 |
| 2 | SRR8943032 | — | — | 0.814 |
| 3 | 156a3def-5866-4be4-ad0b-61b957d5b6eb | — | — | 0.813 |
| 4 | SRR27320698 | — | — | 0.810 |
| 5 | f3781318-56be-4a43-b72d-a6bb65ef9a88 | — | — | 0.763 |
| 6 | TCGA-CN-6022-01A-21R-1686-07 | — | — | 0.762 |
| 7 | BS_C41DJZ1F | high-grade glioma | — | 0.756 |
| 8 | DRR168609 | — | — | 0.756 |
| 9 | 4b3022ba-0232-493c-b3fc-2447e8cf7113 | — | — | 0.753 |
| 10 | TCGA-A2-A4RX-01A-11R-A266-07 | — | D | 0.751 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.100 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |